Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

1st U.S. Biosimilar Arrives: Zarxio Launches; Legal Saga Ongoing

This article was originally published in Scrip

Executive Summary

The day after Amgen was dealt another blow at the U.S. Court of Appeals for the Federal Circuit in the company's failed attempt to keep Novartis unit Sandoz from launching its biosimilar Zarxio (filgrastim-sndz), the latter firm moved forward with putting the medicine on the U.S. market – the first biologic copycat available to Americans.

You may also be interested in...



Amgen’s Biggest Seller Enbrel Hit By Pricing Pressures, Competition

Amgen signaled future declines in revenue for its top-selling product Enbrel during its third quarter conference call as payer pressure on drug pricing and competition mounts.

Pfizer Sets Inflectra Launch Date; J&J Plans To Fight Back

Pfizer commits to “late November” launch for its biosimilar version of infliximab, partnered with Celltrion, which will be the second biosimilar to reach the US market. Remicade innovator Janssen considers it an “at risk” launch and will continue patent litigation, as well as commercial tactics to protect its market.

Pfizer Sets Inflectra Launch Date; J&J Plans To Fight Back

Pfizer commits to “late November” launch for its biosimilar version of infliximab, partnered with Celltrion, which will be the second biosimilar to reach the US market. Remicade innovator Janssen considers it an “at risk” launch and will continue patent litigation, as well as commercial tactics to protect its market.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC029671

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel